PubMed · 1997 · 45 citations · 25 references
Intravesical BCG instillations induce a transient (less than 6 months) peripheral immune activation against several purified BCG antigens and among them the fibronectin binding antigen 85 complex. Reactivation is observed in most cases after additional BCG courses. The absence of long lasting immune activation after a single 6-week course of BCG could be related to the increased clinical efficacy observed with BCG maintenance instillations.
25
Carl Nathan, Henry W. Murray, Michael E. Wiebe et al. · The Journal of Experimental Medicine · 1983 · 1.9K citations · Full text
<i>p53</i> Status and the Efficacy of Cancer Therapy in Vivo
Scott W. Lowe, Stephan Bodis, Andrea I. McClatchey et al. · Science · 1994 · 1.5K citations
T-Cell Subsets Required for Intravesical BCG Immunotherapy for Bladder Cancer
Timothy L. Ratliff, Julie Ritchey, Jerry J.J. Yuan et al. · The Journal of Urology · 1993 · 290 citations